EMA to revise five-year road map in light of feedback
This article was originally published in SRA
The European Medicines Agency is to revise its road map, which sets out its strategic development plans for the next five years to 2015, to take into account the feedback it has received so far1. Part of the road map's vision is for regulators and industry to start working together earlier in the drug development process in order to improve the chances of approval2.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.